FDA and Supplements

The discussion highlights the shifting landscape of dietary supplements, particularly NMN and NAC, in light of recent FDA rulings. A clinical trial on NMN has reclassified it as an experimental drug, restricting its sale as a supplement. Meanwhile, NAC's status has faced similar challenges, raising questions about the influence of lobbying versus scientific evidence in regulatory decisions.